


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously submitted) A compound of the formula:



or the pharmaceutically acceptable acid salts thereof wherein:


R₁ is halogen or C₁-C₄ alkyl;

R₂ and R₃ are the same or different and represent hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino, with the proviso that R₂ and R₃ may not be 2-isopropoxyl and hydrogen respectively when R₁ is bromo;

wherein in an assay for D₂ receptor binding the compound exhibits a K_i value of greater than 300 nM.

2. (Original) A compound according to Claim 1, wherein R₁ is methyl.

3. (Previously submitted) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_x is fluorine, chlorine, bromine, or iodine; and


R_2 and R_3 are the same or different and represent hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a K_i value of greater than 300 nM.


4. (Original) A compound according to Claim 3, wherein R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_1 is bromo.

5. (Original) A compound according to claim 3, wherein R_x is chloride; R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_1 is bromo; R_2 is chloride, methyl or methoxy; and R_3 is hydrogen or methyl.

6. (Original) A compound according to claim 5, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



7. (Previously submitted) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_a is C_1 - C_4 alkyl; and


R_2 and R_3 are the same or different and represent hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a K_i value of greater than 300 nM.


8. (Original) A compound according to Claim 7, wherein R_1 is methyl.

9. (Original) A compound of according to Claim 7, wherein R_2 is chloride, fluoride, methyl or methoxy; and R_3 is hydrogen or methyl.

10. (Original) A compound according to claim 8, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



11. (Previously submitted) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein:

R₁ is C₁-C₄ alkyl or halogen; and

wherein in an assay for D2 receptor binding the compound exhibits a K_i value of greater than 300 nM.

12. (Original) A compound according to Claim 11, wherein R₁ is chloro.

13-35.. (Canceled)

36. (New) A compound according to claim 1 wherein the K_i value is greater than 600 nM.

37. (New) A compound according to claim 1 wherein the K_i value is greater than 1000 nM.

38. (New) A compound according to claim 3 wherein the K_i value of greater than 600 nM.

39. (New) A compound according to claim 3 wherein the K_i value is greater than 1000 nM.


40. (New) A compound according to claim 7 wherein the K_i value is greater than 600 nM.

41. (New) A compound according to claim 7 wherein the K_i value is greater than 1000 nM.

42. (New) A compound according to claim 11 wherein the K_i value is greater than 600 nM.

43. (New) A compound according to claim 11 wherein the K_i value is greater than 1000 nM.

44. (New) A compound of the formula:



or the pharmaceutically acceptable acid salts thereof wherein:


R₁ is halogen or C₁-C₄ alkyl;

R₂ and R₃ are the same or different and represent hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino, with the proviso that R₂ and R₃ may not be 2-isopropoxyl and hydrogen respectively when R₁ is bromo;

wherein in an assay for D₄ receptor binding the compound exhibits a K_i value of 16 nM or less.

45. (New) A compound according to Claim 44, wherein R₁ is methyl.

46. (New) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_x is fluorine, chlorine, bromine, or iodine; and


R₂ and R₃ are the same or different and represent hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D₄ receptor binding the compound exhibits a K_i value of 16 nM or less.


47. (New) A compound according to Claim 46, wherein R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_1 is bromo.

48. (New) A compound according to claim 46, wherein R_x is chloride; R_2 and R_3 may not be 2-isopropoxyl and hydrogen, respectively, when R_1 is bromo; R_2 is chloride, methyl or methoxy; and R_3 is hydrogen or methyl.

49. (New) A compound according to claim 48, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



50. (New) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_a is C_1 - C_4 alkyl; and


R_2 and R_3 are the same or different and represent hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D4 receptor binding the compound exhibits a K_i value of 16 nM or less.


51. (New) A compound according to Claim 50, wherein R_1 is methyl.

52. (New) A compound of according to Claim 50, wherein R_2 is chloride, fluoride, methyl or methoxy; and R_3 is hydrogen or methyl.

53. (New) A compound according to claim 51, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



54. (New) A compound of the formula:




or the pharmaceutically acceptable salts thereof wherein:

R_1 is C_1 - C_4 alkyl or halogen; and

wherein in an assay for D4 receptor binding the compound exhibits a K_i value of 16 nM or less.

55. (New) A compound according to Claim 54, wherein R_1 is chloro.

56. (New) A compound of the formula:



or the pharmaceutically acceptable acid salts thereof wherein:


R₁ is halogen or C₁-C₄ alkyl;

R₂ and R₃ are the same or different and represent hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino, with the proviso that R₂ and R₃ may not be 2-isopropoxyl and hydrogen respectively when R₁ is bromo;

wherein in an assay for D₂ receptor binding the compound exhibits a K_i value of greater than 300 nM, and wherein in an assay for D₄ receptor binding the compound exhibits a K_i value of 16 nM or less.

57. (New) A compound according to Claim 56, wherein R₁ is methyl.

58. (New) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_x is fluorine, chlorine, bromine, or iodine; and


R₂ and R₃ are the same or different and represent hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D₂ receptor binding the compound exhibits a K_i value of greater than 300 nM, and wherein in an assay for D₄ receptor binding the compound exhibits a K_i value of 16 nM or less.


59. (New) A compound according to Claim 58, wherein R₂ and R₃ may not be 2-isopropoxyl and hydrogen, respectively, when R₁ is bromo.

60. (New) A compound according to claim 58; wherein R_x is chloride; R₂ and R₃ may not be 2-isopropoxyl and hydrogen, respectively, when R₁ is bromo; R₂ is chloride, methyl or methoxy; and R₃ is hydrogen or methyl.

61. (New) A compound according to claim 60, wherein the phenyl group substituted with R₂ and R₃ is selected from the group consisting of:



62. (New) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R_a is C_1 - C_4 alkyl; and

R_2 and R_3 are the same or different and represent hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;


wherein in an assay for D2 receptor binding the compound exhibits a K_i value of greater than 300 nM, and wherein in

an assay for D4 receptor binding the compound exhibits a K_i value of 16 nM or less.


63. (New) A compound according to Claim 62, wherein R_1 is methyl.

64. (New) A compound of according to Claim 62, wherein R_2 is chloride, fluoride, methyl or methoxy; and R_3 is hydrogen or methyl.

65. (New) A compound according to claim 63, wherein the phenyl group substituted with R_2 and R_3 is selected from the group consisting of:



66. (New) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein:

R₁ is C₁-C₄ alkyl or halogen; and

wherein in an assay for D2 receptor binding the compound exhibits a K_i value of greater than 300 nM, and wherein in an assay for D4 receptor binding the compound exhibits a K_i value of 16 nM or less.

67. (New) A compound according to Claim 66, wherein R₁ is chloro.